Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,178 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Real-world application of tumor mutational burden-high (TMB-high) and microsatellite instability (MSI) confirms their utility as immunotherapy biomarkers.
Palmeri M, Mehnert J, Silk AW, Jabbour SK, Ganesan S, Popli P, Riedlinger G, Stephenson R, de Meritens AB, Leiser A, Mayer T, Chan N, Spencer K, Girda E, Malhotra J, Chan T, Subbiah V, Groisberg R. Palmeri M, et al. Among authors: chan t, chan n. ESMO Open. 2022 Feb;7(1):100336. doi: 10.1016/j.esmoop.2021.100336. Epub 2021 Dec 23. ESMO Open. 2022. PMID: 34953399 Free PMC article.
First-in-Human Clinical Trial of Oral ONC201 in Patients with Refractory Solid Tumors.
Stein MN, Bertino JR, Kaufman HL, Mayer T, Moss R, Silk A, Chan N, Malhotra J, Rodriguez L, Aisner J, Aiken RD, Haffty BG, DiPaola RS, Saunders T, Zloza A, Damare S, Beckett Y, Yu B, Najmi S, Gabel C, Dickerson S, Zheng L, El-Deiry WS, Allen JE, Stogniew M, Oster W, Mehnert JM. Stein MN, et al. Among authors: chan n. Clin Cancer Res. 2017 Aug 1;23(15):4163-4169. doi: 10.1158/1078-0432.CCR-16-2658. Epub 2017 Mar 22. Clin Cancer Res. 2017. PMID: 28331050 Free PMC article. Clinical Trial.
Immune Activation and Benefit From Avelumab in EBV-Positive Gastric Cancer.
Panda A, Mehnert JM, Hirshfield KM, Riedlinger G, Damare S, Saunders T, Kane M, Sokol L, Stein MN, Poplin E, Rodriguez-Rodriguez L, Silk AW, Aisner J, Chan N, Malhotra J, Frankel M, Kaufman HL, Ali S, Ross JS, White EP, Bhanot G, Ganesan S. Panda A, et al. Among authors: chan n. J Natl Cancer Inst. 2018 Mar 1;110(3):316-320. doi: 10.1093/jnci/djx213. J Natl Cancer Inst. 2018. PMID: 29155997 Free PMC article.
Inference of Germline Mutational Status and Evaluation of Loss of Heterozygosity in High-Depth, Tumor-Only Sequencing Data.
Khiabanian H, Hirshfield KM, Goldfinger M, Bird S, Stein M, Aisner J, Toppmeyer D, Wong S, Chan N, Dhar K, Gheeya J, Vig H, Hadigol M, Pavlick D, Ansari S, Ali S, Xia B, Rodriguez-Rodriguez L, Ganesan S. Khiabanian H, et al. Among authors: chan n. JCO Precis Oncol. 2018;2018:PO.17.00148. doi: 10.1200/PO.17.00148. Epub 2018 Jan 19. JCO Precis Oncol. 2018. PMID: 30246169 Free PMC article.
Safety and enhanced immunostimulatory activity of the DRD2 antagonist ONC201 in advanced solid tumor patients with weekly oral administration.
Stein MN, Malhotra J, Tarapore RS, Malhotra U, Silk AW, Chan N, Rodriguez L, Aisner J, Aiken RD, Mayer T, Haffty BG, Newman JH, Aspromonte SM, Bommareddy PK, Estupinian R, Chesson CB, Sadimin ET, Li S, Medina DJ, Saunders T, Frankel M, Kareddula A, Damare S, Wesolowsky E, Gabel C, El-Deiry WS, Prabhu VV, Allen JE, Stogniew M, Oster W, Bertino JR, Libutti SK, Mehnert JM, Zloza A. Stein MN, et al. Among authors: chan n. J Immunother Cancer. 2019 May 22;7(1):136. doi: 10.1186/s40425-019-0599-8. J Immunother Cancer. 2019. PMID: 31118108 Free PMC article. Clinical Trial.
Durable Response to PD1 Inhibitor Pembrolizumab in a Metastatic, Metaplastic Breast Cancer.
Gorshein E, Matsuda K, Riedlinger G, Sokol L, Rodriguez-Rodriguez L, Eladoumikdachi F, Grandhi M, Ganesan S, Toppmeyer DL, Potdevin L, Toomey K, Hirshfield KM, Chan N. Gorshein E, et al. Among authors: chan n. Case Rep Oncol. 2021 Jun 18;14(2):931-937. doi: 10.1159/000515510. eCollection 2021 May-Aug. Case Rep Oncol. 2021. PMID: 34248561 Free PMC article.
A phase I study of veliparib with cyclophosphamide and veliparib combined with doxorubicin and cyclophosphamide in advanced malignancies.
Tan AR, Chan N, Kiesel BF, Stein MN, Moss RA, Malhotra J, Aisner J, Shah M, Gounder M, Lin H, Kane MP, Lin Y, Ji J, Chen A, Beumer JH, Mehnert JM. Tan AR, et al. Among authors: chan n. Cancer Chemother Pharmacol. 2022 Jan;89(1):49-58. doi: 10.1007/s00280-021-04350-x. Epub 2021 Oct 20. Cancer Chemother Pharmacol. 2022. PMID: 34669023 Free PMC article. Clinical Trial.
A phase I study of talazoparib (BMN 673) combined with carboplatin and paclitaxel in patients with advanced solid tumors (NCI9782).
Leal TA, Sharifi MN, Chan N, Wesolowski R, Turk AA, Bruce JY, O'Regan RM, Eickhoff J, Barroilhet LM, Malhotra J, Mehnert J, Girda E, Wiley E, Schmitz N, Andrews S, Liu G, Wisinski KB. Leal TA, et al. Among authors: chan n. Cancer Med. 2022 Nov;11(21):3969-3981. doi: 10.1002/cam4.4724. Epub 2022 Apr 8. Cancer Med. 2022. PMID: 35396812 Free PMC article. Clinical Trial.
Phase I trial of daily subcutaneous SPL-108 injections in combination with paclitaxel in patients with platinum resistant CD44+ advanced ovarian epithelial cancer.
Girda E, Hou J, Nelson D, Finlayson M, de Meritens AB, Chekmareiva M, Leiser A, Song M, Stephenson R, Chan N, Tergas AI, Vattakalam R, Wright JD, Yu H, Martincuks A, Kohut A, Palmer J, Rodriguez-Rodriguez L. Girda E, et al. Among authors: chan n. Int J Gynecol Cancer. 2022 Jun 24;32(8):1032-8. doi: 10.1136/ijgc-2021-003316. Online ahead of print. Int J Gynecol Cancer. 2022. PMID: 35750354 Free PMC article.
1,178 results